Immunai Inc., an artificial intelligence biotechnology company, announced on Thursday a multi-year collaboration in immunology and immuno-oncology programs with Teva Pharmaceuticals. Immunology is ...

TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped. The European ...

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing ...

Teva Pharmaceutical Industries (NYSE:TEVA) and Alvotech (NASDAQ:ALVO) said the FDA has expanded labeling for its biosimilar of Johnson & Johnson’s (JNJ) Stelara to include the treatment of Crohn ...

Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine into its model, noting TEV-749’s sales ...

European Union antitrust authorities fined Israel’s Teva Pharmaceuticals TEVA1.92%increase; green up pointing triangle 462.6 million euros ($502.3 million), saying the company abused its market ...

Shares of Teva Pharmaceutical Industries Ltd. (TEVA) have gained 2.9% over the past four weeks to close the last trading session at $18.25, but there could still be a solid upside left in the ...

In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus TEVA, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ...